Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Moshe Talpaz, MD
University of Michigan Rogel Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Margaret Hospital
Toronto, Ontario, Canada
- Emory University Hospital
Atlanta, Georgia, United States
- the University of Chicago Medical Center
Chicago, Illinois, United States
- Dana Farber Cancer Institute (and Massachusetts General)
Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- the Ohio State University Medical Center
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2008
- Primary completion
- 30 Apr 2009
- Completion
- 3 Sept 2014
- Last update posted
- 2 Jun 2017
- Registered enrollment
- 74
- Registry id
- NCT00724568
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.